Investors ignore a 3rd negative report from short-seller Citron Research on medical device company Intuitive Surgical, sending shares up slightly today.

Investors, who sent shares of Intuitive Surgical (NSDQ:ISRG) down 10% the 1st time Citron Research issued a negative report on the medical device company, yawned today at a 3rd missive from the short seller.
ISRG shares were up slightly as of about 3:30 p.m. today to $561.07 apiece, despite Citron's repeated assertion that the stock is headed for $300 per share.
The millions of dollars in fees that medical device companies pay for FDA review aren't exempt from...
EnteroMedics expects to file for pre-market approval from the FDA this quarter for its Maestro vagal...
Natus Medical beats Wall Street's earnings forecast with a 1,000-fold profit surge on record sales,...
The U.S. Supreme Court agrees to hear Medtronic's appeal of a patent infringement loss to rival...
The New York Times lists the 10 most expensive hospitals in the United States, based on CMS data